|
|
Post by winstonsmith on Jan 26, 2017 22:07:45 GMT -5
I'm pretty sure if you didn't sell you haven't lost anything.
|
|
|
|
Post by longliner on Jan 26, 2017 22:09:12 GMT -5
I have no intention of losing anything.
|
|
|
|
Post by kball on Jan 26, 2017 22:42:53 GMT -5
I'm pretty sure if you didn't sell you haven't lost anything. Crazy talk. Just like homeowners with mortgages lost nothing during the financial crisis? |
|
|
|
Post by careful2invest on Jan 26, 2017 23:17:59 GMT -5
There is simply no good reason to delay the sharing of any good news. Those six words again... "It just does not make sense" |
|
|
|
Post by ezrasfund on Jan 27, 2017 0:26:54 GMT -5
I just visited my brother in Australia. His son is 10 years old and was diagnosed as a Type 1 diabetic two years ago. Both parents are scientists and my nephew is a brilliant young naturalist himself. He uses a MiniMed pump, and his parents try to keep his life as normal as possible; letting him eat what everyone else is eating, bolusing at mealtime and not before, trying to be relaxed about his routine (which was more difficult when I saw him on vacation). He has access to the finest money can buy in Australian medicine, but not quite everything available here, including a slightly inferior CGM. His blood sugar control is OK but not great. (I just observed and did not ask intrusive questions.) His parents are always worried and routinely check his blood a near midnight and again at 3 am. He has minor issues with skin irritations around his pump site.
Bottom line is that this kid could certainly use a safer, easier, less intrusive and less costly therapy. Right now his parents are looking forward to a new CGM that will be available to them in two years. As Phd. scientists they feel they have a rigorous understanding of the disease and are not interested in considering anything that hasn't been well proven. My take away is that this boy could certainly benefit from Afrezza when he is older, but it will take many years before its efficacy and safety is proven in the eyes of scientists whose training is to be skeptical of any new idea.
Also, of course, a typical mealtime bolus was about 1.5 units equivalent and we are still waiting for pediatric studies and 2 unit cartridges. So Afrezza should be a success, just maybe not in our lifetimes.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2017 7:42:46 GMT -5
As Phd. scientists they feel they have a rigorous understanding of the disease and are not interested in considering anything that hasn't been well proven. My take away is that this boy could certainly benefit from Afrezza when he is older, but it will take many years before its efficacy and safety is proven in the eyes of scientists whose training is to be skeptical of any new idea. If they had a basic understanding of diabetes they would understand that insulin is the only solution. Only Afrezza provides that solution. |
|
|
|
Post by kbrion77 on Jan 27, 2017 7:58:08 GMT -5
As Phd. scientists they feel they have a rigorous understanding of the disease and are not interested in considering anything that hasn't been well proven. My take away is that this boy could certainly benefit from Afrezza when he is older, but it will take many years before its efficacy and safety is proven in the eyes of scientists whose training is to be skeptical of any new idea. If they had a basic understanding of diabetes they would understand that insulin is the only solution. Only Afrezza provides that solution. Such a naive comment. |
|
|
|
Post by silentknight on Jan 27, 2017 8:10:58 GMT -5
As Phd. scientists they feel they have a rigorous understanding of the disease and are not interested in considering anything that hasn't been well proven. My take away is that this boy could certainly benefit from Afrezza when he is older, but it will take many years before its efficacy and safety is proven in the eyes of scientists whose training is to be skeptical of any new idea. If they had a basic understanding of diabetes they would understand that insulin is the only solution. Only Afrezza provides that solution. As PhD holders and the parents of a child with diabetes, I think it's safe to say that their education, intellectual ability and real-life experience would make it very clear to them that insulin is what is needed for diabetics, despite what your condescending post suggests. It's something they've known for a while which is why their son is on a pump. If ezra described them accurately, I'd wager their understanding of the disease would outpace yours, mine or many others on this board, short of an endo or healthcare professional specializing in diabetes. To say Afrezza is the only solution is unequivocally false. There are several other insulins on the market that also do what Afrezza does; manage blood glucose levels. Afrezza is not the ONLY solution to their son's problem, as evidenced by his current use of the pump. Afrezza might be the best and most effective (but also not available in Australia yet), but it's simply not the only one available. That line of thinking, to me, explains why many here simply can't fathom that Afrezza might fail. There is a huge disconnect with people in understanding that a product's efficacy and marketability are completely separate things and one does not determine the other. Afrezza is a commercial dud, despite it's efficacy. It's efficacy also will not guarantee that it succeeds, as you suggest in your post and many others would like to believe. Patients with diabetes do not REQUIRE Afrezza to manage their disease as you suggest, and we've seen as much as endos and insurance companies that are unwilling to use the product with patients outside of a few hundred per week. Afrezza is not the only solution to the problem. It has competitors in the prandial insulin space and currently, those competitors are destroying it in the commercialization arena. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2017 8:21:03 GMT -5
Obviously, people cannot differentiate insulin from analogues; Afrezza is the only insulin available.
|
|
|
|
Post by esstan2001 on Jan 27, 2017 8:21:18 GMT -5
I just visited my brother in Australia. His son is 10 years old and was diagnosed as a Type 1 diabetic two years ago. Both parents are scientists and my nephew is a brilliant young naturalist himself. He uses a MiniMed pump, and his parents try to keep his life as normal as possible; letting him eat what everyone else is eating, bolusing at mealtime and not before, trying to be relaxed about his routine (which was more difficult when I saw him on vacation). He has access to the finest money can buy in Australian medicine, but not quite everything available here, including a slightly inferior CGM. His blood sugar control is OK but not great. (I just observed and did not ask intrusive questions.) His parents are always worried and routinely check his blood a near midnight and again at 3 am. He has minor issues with skin irritations around his pump site. Bottom line is that this kid could certainly use a safer, easier, less intrusive and less costly therapy. Right now his parents are looking forward to a new CGM that will be available to them in two years. As Phd. scientists they feel they have a rigorous understanding of the disease and are not interested in considering anything that hasn't been well proven. My take away is that this boy could certainly benefit from Afrezza when he is older, but it will take many years before its efficacy and safety is proven in the eyes of scientists whose training is to be skeptical of any new idea. Also, of course, a typical mealtime bolus was about 1.5 units equivalent and we are still waiting for pediatric studies and 2 unit cartridges. So Afrezza should be a success, just maybe not in our lifetimes. ezra, the info on the PK/PD profile; the mimicry of first phase insulin release like a human pancreas, the fact that it is human insulin, and all the social media 'anecdotal' results... even some of the more recent scientific journal publications... if you make the case for them surely they would at least consider... sportsrancho has family friends with kids on Afrezza. Put your brother in touch with them through this board... For your nephew it is worth the effort and at least worth trying for him, with the reduced chances of hypos. Good luck. (of course, there is still the issue of getting him a script in a country where it has yet to be approved...) |
|
|
|
Post by silentknight on Jan 27, 2017 8:33:21 GMT -5
Obviously, people cannot differentiate insulin from analogues; Afrezza is the only insulin available. I understand it well enough. Other insulin has had its chemical structure changed on a molecular level while Afrezza has not. Yet it still is effective in treating the disease, despite what you suggest. That's why the standard of care is what it is currently. Perhaps you should start a world tour to stop in and educate every diabetes patient and endo on earth to inform them that they're all wrong and that Afrezza is the only real way to treat diabetes since it's not an analog. Spreading the word about Afrezza is what's needed after all... |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2017 8:41:41 GMT -5
Silent: you are either in denial or a fudster. If the analogues were identical to insulin, people using the analogues would not have hypos and vascular damage leading to amputation and organ failure.
Enough said!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 27, 2017 8:44:48 GMT -5
Obviously, people cannot differentiate insulin from analogues; Afrezza is the only insulin available. I understand it well enough. Other insulin has had its chemical structure changed on a molecular level while Afrezza has not. Yet it still is effective in treating the disease, despite what you suggest. That's why the standard of care is what it is currently. Perhaps you should start a world tour to stop in and educate every diabetes patient and endo on earth to inform them that they're all wrong and that Afrezza is the only real way to treat diabetes since it's not an analog. Spreading the word about Afrezza is what's needed after all... I would have thought that social media would have had a greater impact on spreading the word. The current standard of care is outdated but it what is well known and understood, but less than optimal. Unfortunately, it takes time to build awareness and trust and doctors practicing defensive medicine does not help our cause but docs behave like, well people and all of us are to some extent risk averse especially those that need a medical license to make a living. A1c remains a benchmark measurement but with CGMs, the information provided by A1c is not nearly as valuable as it once was. Metformin is also a standard of care as are RAAs but as we all know, for most people with diabetes, if we wired them up to a CGM with their current regiment of care for a few months and then did the same after they went on Afrezza (with a few weeks to learn how to dose it) the numbers the patient would achieve would be significantly better with Afrezza. Its easier and loads better but its also vastly different. If the new sales team is good, given we have better samples and titration packs, the ratio of patients trying / patients using ongoing should improve in a few weeks and NRx will measure if this is the case. My expectation is that by 2-17 we should start to see consistent W/W growth in NRx. Small at first perhaps but consistent. Hopefully we get a reprieve from the delisting. At this point, if the commercialization strategy is right and properly executed, even with a smaller sales force, the Rx growth trend with an extra few months runway prior to a potential delisting would get SP > $1.00 |
|
|
|
Post by op2778 on Jan 27, 2017 8:53:15 GMT -5
I respect all idea and opinions. Barely post here, just because ppl repeat over and over the same things....
But, i read this and i said: i need to say something:
"scientists whose training is to be skeptical of any new idea". This is really what scientist has to be? Skeptical of any new idea? Holy cow, if that is the truth, why in hell, we have so many scientist in the world trying to find cure to terrific diseases?
That said, i'm not children parent, like u said probably when he gets older and Afrezza will reach Australia, they will start to study about it.
Op
|
|
|
|
Post by kball on Jan 27, 2017 8:53:32 GMT -5
It has dawned on me that many of us here now know more than we want about diabetes.
And less than we need about investing
|
|
